yvandenbroek
/
sprookjes
/
Login
Register
TriplyDB
sprookjes
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
2
Q38798481-2FC8651E-2124-476D-BEE1-4D31E1C74973
Q38798481-2FC8651E-2124-476D-BEE1-4D31E1C74973
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38798481-2FC8651E-2124-476D-BEE1-4D31E1C74973
Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates.
P2860
Q38798481-2FC8651E-2124-476D-BEE1-4D31E1C74973
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38798481-2FC8651E-2124-476D-BEE1-4D31E1C74973
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
a6fec713c764e7fdbcac2c5fc70bef88655d40c0
P2860
Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors.